A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease

@article{Karaman2004A1S,
  title={A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease},
  author={Yahya Karaman and F. Erdoğan and E. K{\"o}seoğlu and Tayfun Turan and A. Ersoy},
  journal={Dementia and Geriatric Cognitive Disorders},
  year={2004},
  volume={19},
  pages={51 - 56}
}
  • Yahya Karaman, F. Erdoğan, +2 authors A. Ersoy
  • Published 2004
  • Psychology, Medicine
  • Dementia and Geriatric Cognitive Disorders
  • The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713), in patients with advanced moderate Alzheimer’s disease (AD) was evaluated in a 12-month placebo-controlled study. We aimed to investigate whether there was any evidence for the benefits of rivastigmine in patients with severe disease. These patients were compared with matched controls. In this study, 24 patients with advanced moderate AD received rivastigmine for 12 months. Another 20 patients received… CONTINUE READING

    Tables and Topics from this paper.

    Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
    • 595
    • Highly Influenced
    • Open Access
    Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors
    • 28
    • Highly Influenced
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 58 REFERENCES
    Commentary: Another piece of the Alzheimer's jigsaw.
    • 472
    • Open Access